Exclusive Summary

• - 1.6 mg Thymalfasin injection is off‑patent, originator launched in the 1990s, and generics have been present for >20 years in China—no global patent barriers for expansion.
• - Targets large unmet supportive‑care segments: ~254 million with chronic HBV, ~50 million with chronic HCV, and ~48.9 million annual sepsis cases worldwide.
• - Not on the WHO Essential Medicines List and not first‑line in major global guidelines, yet registered and used in countries like the Philippines, with hospital‑level acceptance as an immunomodulatory adjunct.
• - Competition is dense in China (>20 manufacturers) but remains limited across many SEA/MENA/LatAm markets; existing PH registration and PH‑FDA GMP enable rapid distribution and regional roll‑out.
• - Offers ~30–50% cost savings versus originator brands, combining compliance and registration experience to win hospital tenders and formulary inclusion.